Drug Trial Radar · NCT02106494
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
942
Actual
Start
Mar 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Heron TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 87 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (\> 24-120 hours) complete response (CR) rate (defined as no emesis and no use of rescue medications) in subjects receiving highly emetogenic chemotherapy (HEC) as defined by the 2011 ASCO CINV guidelines
Conditions
- Chemotherapy-induced Nausea and Vomiting
Interventions
APF530Drug
OndansetronDrug
Ondansetron placeboDrug
APF530 placeboDrug
FosaprepitantDrug
DexamethasoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Delayed Phase Complete Response (CR) RateTime frame: 24 - 120 Hours
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Arizona Oncology Associates, PC-HAL
Phoenix, Arizona
The Oncology Institute of Hope and Innovation
Downey, California
Compassionate Cancer Medical Center
Riverside, California
Northern Indiana Research
Mishawaka, Indiana
Northern Indiana Research
South Bend, Indiana
North Shore Oncology
East Setauket, New York
Gabrail Cancer Center Research
Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.